• LAST PRICE
    2.5500
  • TODAY'S CHANGE (%)
    Trending Up0.4800 (23.1884%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    2.5500 / 2.0700
  • Day Range
    Low 2.5500
    High 2.5500
  • 52 Week Range
    Low 0.6302
    High 17.7000
  • Volume
    1,540
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 2.55
TimeVolumeLADX
01:06 ET13002.55
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLADX
LadRx Corp
1.0M
4.4x
---
United StatesMHTX
Manhattan Scientifics Inc
962.0K
-0.8x
---
United StatesVGLS
VG Life Sciences Inc
1.1M
0.0x
---
United StatesGSTC
GlobeStar Therapeutics Corp
988.5K
-0.4x
---
United StatesCAPS
Capstone Holding Corp
819.6K
-0.8x
---
United StatesEVLO
Evelo Biosciences Inc
776.2K
0.0x
---
As of 2024-04-13

Company Information

LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.

Contact Information

Headquarters
11726 San Vicente Boulevard, Suite 650LOS ANGELES, CA, United States 90049
Phone
310-826-5648
Fax
310-826-6139

Executives

Non-Executive Chairman of the Board, Independent Director
Jennifer Simpson
Chief Executive Officer
Stephen Snowdy
Chief Financial Officer, Senior Vice President, Treasurer
John Caloz
Independent Director
Joel Caldwell
Independent Director
Cary Claiborne

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.0M
Revenue (TTM)
$0.00
Shares Outstanding
495.1K
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.69
EPS
$0.59
Book Value
$0.22
P/E Ratio
4.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
3.0x
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.